Kymera Therapeutics Statistics
Share Statistics
Kymera Therapeutics has 65.12M
shares outstanding. The number of shares has increased by 5.84%
in one year.
Shares Outstanding | 65.12M |
Shares Change (YoY) | 5.84% |
Shares Change (QoQ) | 0.28% |
Owned by Institutions (%) | 94.22% |
Shares Floating | n/a |
Failed to Deliver (FTD) Shares | 262 |
FTD / Avg. Volume | 0.03% |
Short Selling Information
The latest short interest is 7M, so 10.74% of the outstanding
shares have been sold short.
Short Interest | 7M |
Short % of Shares Out | 10.74% |
Short % of Float | 13.57% |
Short Ratio (days to cover) | 10.74 |
Valuation Ratios
The PE ratio is -13.49 and the forward
PE ratio is -10.98.
Kymera Therapeutics's PEG ratio is
-0.74.
PE Ratio | -13.49 |
Forward PE | -10.98 |
PS Ratio | 64.14 |
Forward PS | 4.9 |
PB Ratio | 3.61 |
P/FCF Ratio | -14.56 |
PEG Ratio | -0.74 |
Financial Ratio History Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Kymera Therapeutics.
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.53,
with a Debt / Equity ratio of 0.11.
Current Ratio | 7.53 |
Quick Ratio | 7.53 |
Debt / Equity | 0.11 |
Debt / EBITDA | -0.41 |
Debt / FCF | -0.42 |
Interest Coverage | -1050.74 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity | n/a |
Return on Assets | n/a |
Return on Invested Capital | n/a |
Revenue Per Employee | $226,307.69 |
Profits Per Employee | $-1,076,240.38 |
Employee Count | 208 |
Asset Turnover | 0.05 |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by 36.44% in the
last 52 weeks. The beta is 2.19, so Kymera Therapeutics's
price volatility has been higher than the market average.
Beta | 2.19 |
52-Week Price Change | 36.44% |
50-Day Moving Average | 29.62 |
200-Day Moving Average | 39.47 |
Relative Strength Index (RSI) | 74.96 |
Average Volume (20 Days) | 801,785 |
Income Statement
In the last 12 months, Kymera Therapeutics had revenue of 47.07M
and earned -223.86M
in profits. Earnings per share was -2.98.
Revenue | 47.07M |
Gross Profit | 39.7M |
Operating Income | -261.63M |
Net Income | -223.86M |
EBITDA | -216.24M |
EBIT | -223.61M |
Earnings Per Share (EPS) | -2.98 |
Full Income Statement Balance Sheet
The company has 120.26M in cash and 87.76M in
debt, giving a net cash position of 32.49M.
Cash & Cash Equivalents | 120.26M |
Total Debt | 87.76M |
Net Cash | 32.49M |
Retained Earnings | -754.61M |
Total Assets | 918.31M |
Working Capital | 441.96M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -194.5M
and capital expenditures -12.84M, giving a free cash flow of -207.34M.
Operating Cash Flow | -194.5M |
Capital Expenditures | -12.84M |
Free Cash Flow | -207.34M |
FCF Per Share | -2.76 |
Full Cash Flow Statement Margins
Gross margin is 84.34%, with operating and profit margins of -555.82% and -475.57%.
Gross Margin | 84.34% |
Operating Margin | -555.82% |
Pretax Margin | -475.57% |
Profit Margin | -475.57% |
EBITDA Margin | -459.37% |
EBIT Margin | -555.82% |
FCF Margin | -440.47% |